Direct effects of Tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: Integrated data analyses from 4 placebo controlled clinical studies

Gerald B. Brock, Kevin T. McVary, Claus Roehrborn, Steven Watts, Xiao Ni, Lars Viktrup, David G. Wong, Craig Donatucci

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose Tadalafil has regulatory approval for the treatment of men with signs/symptoms of benign prostatic hyperplasia with and without erectile dysfunction. We assessed whether the effects of treatment with tadalafil for lower urinary tract symptoms/benign prostatic hyperplasia are independent of improvements in erectile dysfunction. Materials and Methods Four separate analyses used integrated data from 4 randomized, double-blind, placebo controlled studies in men with lower urinary tract symptoms/benign prostatic hyperplasia with and without erectile dysfunction to test whether total I-PSS (International Prostate Symptom Score) improvement was due to improvement in IIEF-EF (International Index of Erectile Function-Erectile Function domain score). Unidirectional and bidirectional path analysis models determined direct and indirect treatment effects mediated by improvements in lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction symptoms. Results A total of 1,496 men, of whom 77% had erectile dysfunction, received at least 1 dose of tadalafil 5 mg once daily or placebo. The placebo adjusted treatment effect for men with erectile dysfunction was represented by a mean decrease of -2.3 (p <0.0001) in total I-PSS vs -2.2 (p = 0.0007) for men without erectile dysfunction. The correlation between change from baseline in total I-PSS and IIEF-EF was weak (r2 = 0.08, p <0.0001). The unidirectional path analysis model suggested that the total treatment effect on total I-PSS score improvement (2.25) was derived from a direct treatment effect of 1.57 (70%, p <0.001) and an indirect treatment effect of 0.67 (30% via IIEF-EF improvement, p <0.001). Bidirectional path analysis showed that total I-PSS improvement was largely attributed to direct (92.5%, p <0.001) vs indirect (7.5%, p = 0.32) treatment effects via IIEF-EF improvement. Conclusions Regardless of the analytical approach, self-reported erectile dysfunction status did not appreciably influence tadalafil treatment response in men with lower urinary tract symptoms/benign prostatic hyperplasia, supporting the dual action of tadalafil on lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.

Original languageEnglish (US)
Pages (from-to)405-411
Number of pages7
JournalJournal of Urology
Volume191
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Lower Urinary Tract Symptoms
Erectile Dysfunction
Placebos
Prostatic Hyperplasia
Prostate
Therapeutics
Tadalafil
Clinical Studies
Signs and Symptoms

Keywords

  • erectile dysfunction
  • phosphodiesterase 5 inhibitors
  • prostatic hyperplasia
  • tadalafil

ASJC Scopus subject areas

  • Urology

Cite this

Direct effects of Tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement : Integrated data analyses from 4 placebo controlled clinical studies. / Brock, Gerald B.; McVary, Kevin T.; Roehrborn, Claus; Watts, Steven; Ni, Xiao; Viktrup, Lars; Wong, David G.; Donatucci, Craig.

In: Journal of Urology, Vol. 191, No. 2, 02.2014, p. 405-411.

Research output: Contribution to journalArticle

@article{fbe3dc90865d48fabd970314563c45cb,
title = "Direct effects of Tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: Integrated data analyses from 4 placebo controlled clinical studies",
abstract = "Purpose Tadalafil has regulatory approval for the treatment of men with signs/symptoms of benign prostatic hyperplasia with and without erectile dysfunction. We assessed whether the effects of treatment with tadalafil for lower urinary tract symptoms/benign prostatic hyperplasia are independent of improvements in erectile dysfunction. Materials and Methods Four separate analyses used integrated data from 4 randomized, double-blind, placebo controlled studies in men with lower urinary tract symptoms/benign prostatic hyperplasia with and without erectile dysfunction to test whether total I-PSS (International Prostate Symptom Score) improvement was due to improvement in IIEF-EF (International Index of Erectile Function-Erectile Function domain score). Unidirectional and bidirectional path analysis models determined direct and indirect treatment effects mediated by improvements in lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction symptoms. Results A total of 1,496 men, of whom 77{\%} had erectile dysfunction, received at least 1 dose of tadalafil 5 mg once daily or placebo. The placebo adjusted treatment effect for men with erectile dysfunction was represented by a mean decrease of -2.3 (p <0.0001) in total I-PSS vs -2.2 (p = 0.0007) for men without erectile dysfunction. The correlation between change from baseline in total I-PSS and IIEF-EF was weak (r2 = 0.08, p <0.0001). The unidirectional path analysis model suggested that the total treatment effect on total I-PSS score improvement (2.25) was derived from a direct treatment effect of 1.57 (70{\%}, p <0.001) and an indirect treatment effect of 0.67 (30{\%} via IIEF-EF improvement, p <0.001). Bidirectional path analysis showed that total I-PSS improvement was largely attributed to direct (92.5{\%}, p <0.001) vs indirect (7.5{\%}, p = 0.32) treatment effects via IIEF-EF improvement. Conclusions Regardless of the analytical approach, self-reported erectile dysfunction status did not appreciably influence tadalafil treatment response in men with lower urinary tract symptoms/benign prostatic hyperplasia, supporting the dual action of tadalafil on lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.",
keywords = "erectile dysfunction, phosphodiesterase 5 inhibitors, prostatic hyperplasia, tadalafil",
author = "Brock, {Gerald B.} and McVary, {Kevin T.} and Claus Roehrborn and Steven Watts and Xiao Ni and Lars Viktrup and Wong, {David G.} and Craig Donatucci",
year = "2014",
month = "2",
doi = "10.1016/j.juro.2013.09.057",
language = "English (US)",
volume = "191",
pages = "405--411",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Direct effects of Tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement

T2 - Integrated data analyses from 4 placebo controlled clinical studies

AU - Brock, Gerald B.

AU - McVary, Kevin T.

AU - Roehrborn, Claus

AU - Watts, Steven

AU - Ni, Xiao

AU - Viktrup, Lars

AU - Wong, David G.

AU - Donatucci, Craig

PY - 2014/2

Y1 - 2014/2

N2 - Purpose Tadalafil has regulatory approval for the treatment of men with signs/symptoms of benign prostatic hyperplasia with and without erectile dysfunction. We assessed whether the effects of treatment with tadalafil for lower urinary tract symptoms/benign prostatic hyperplasia are independent of improvements in erectile dysfunction. Materials and Methods Four separate analyses used integrated data from 4 randomized, double-blind, placebo controlled studies in men with lower urinary tract symptoms/benign prostatic hyperplasia with and without erectile dysfunction to test whether total I-PSS (International Prostate Symptom Score) improvement was due to improvement in IIEF-EF (International Index of Erectile Function-Erectile Function domain score). Unidirectional and bidirectional path analysis models determined direct and indirect treatment effects mediated by improvements in lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction symptoms. Results A total of 1,496 men, of whom 77% had erectile dysfunction, received at least 1 dose of tadalafil 5 mg once daily or placebo. The placebo adjusted treatment effect for men with erectile dysfunction was represented by a mean decrease of -2.3 (p <0.0001) in total I-PSS vs -2.2 (p = 0.0007) for men without erectile dysfunction. The correlation between change from baseline in total I-PSS and IIEF-EF was weak (r2 = 0.08, p <0.0001). The unidirectional path analysis model suggested that the total treatment effect on total I-PSS score improvement (2.25) was derived from a direct treatment effect of 1.57 (70%, p <0.001) and an indirect treatment effect of 0.67 (30% via IIEF-EF improvement, p <0.001). Bidirectional path analysis showed that total I-PSS improvement was largely attributed to direct (92.5%, p <0.001) vs indirect (7.5%, p = 0.32) treatment effects via IIEF-EF improvement. Conclusions Regardless of the analytical approach, self-reported erectile dysfunction status did not appreciably influence tadalafil treatment response in men with lower urinary tract symptoms/benign prostatic hyperplasia, supporting the dual action of tadalafil on lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.

AB - Purpose Tadalafil has regulatory approval for the treatment of men with signs/symptoms of benign prostatic hyperplasia with and without erectile dysfunction. We assessed whether the effects of treatment with tadalafil for lower urinary tract symptoms/benign prostatic hyperplasia are independent of improvements in erectile dysfunction. Materials and Methods Four separate analyses used integrated data from 4 randomized, double-blind, placebo controlled studies in men with lower urinary tract symptoms/benign prostatic hyperplasia with and without erectile dysfunction to test whether total I-PSS (International Prostate Symptom Score) improvement was due to improvement in IIEF-EF (International Index of Erectile Function-Erectile Function domain score). Unidirectional and bidirectional path analysis models determined direct and indirect treatment effects mediated by improvements in lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction symptoms. Results A total of 1,496 men, of whom 77% had erectile dysfunction, received at least 1 dose of tadalafil 5 mg once daily or placebo. The placebo adjusted treatment effect for men with erectile dysfunction was represented by a mean decrease of -2.3 (p <0.0001) in total I-PSS vs -2.2 (p = 0.0007) for men without erectile dysfunction. The correlation between change from baseline in total I-PSS and IIEF-EF was weak (r2 = 0.08, p <0.0001). The unidirectional path analysis model suggested that the total treatment effect on total I-PSS score improvement (2.25) was derived from a direct treatment effect of 1.57 (70%, p <0.001) and an indirect treatment effect of 0.67 (30% via IIEF-EF improvement, p <0.001). Bidirectional path analysis showed that total I-PSS improvement was largely attributed to direct (92.5%, p <0.001) vs indirect (7.5%, p = 0.32) treatment effects via IIEF-EF improvement. Conclusions Regardless of the analytical approach, self-reported erectile dysfunction status did not appreciably influence tadalafil treatment response in men with lower urinary tract symptoms/benign prostatic hyperplasia, supporting the dual action of tadalafil on lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.

KW - erectile dysfunction

KW - phosphodiesterase 5 inhibitors

KW - prostatic hyperplasia

KW - tadalafil

UR - http://www.scopus.com/inward/record.url?scp=84891919214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891919214&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.09.057

DO - 10.1016/j.juro.2013.09.057

M3 - Article

C2 - 24096120

AN - SCOPUS:84891919214

VL - 191

SP - 405

EP - 411

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -